abstract |
The present invention relates to a novel crystalline form of Gefitinib and a process for its Preparation thereof. Gefitinib is 4-(31-chloro-41-fluoro anilino)-7-methoxy-6- (3-morpholino propoxy) quinazoline and has the structural formula (I). The present invention is to provide a stable novel crystalline form of Gefitinib designated by us as Form-6, and a process for the preparation of the same. Gefitinib is useful in the treatment of a variety of solid tumors, especially non-small cell lung cancer and hematological malignancies. |